JP2015502346A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015502346A5 JP2015502346A5 JP2014541386A JP2014541386A JP2015502346A5 JP 2015502346 A5 JP2015502346 A5 JP 2015502346A5 JP 2014541386 A JP2014541386 A JP 2014541386A JP 2014541386 A JP2014541386 A JP 2014541386A JP 2015502346 A5 JP2015502346 A5 JP 2015502346A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- seq
- item
- disorder
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 230000002092 calcimimetic effect Effects 0.000 claims description 4
- 208000020832 chronic kidney disease Diseases 0.000 claims description 4
- 208000037157 Azotemia Diseases 0.000 claims description 2
- 208000013725 Chronic Kidney Disease-Mineral and Bone disease Diseases 0.000 claims description 2
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 238000000502 dialysis Methods 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 201000006370 kidney failure Diseases 0.000 claims description 2
- 230000004060 metabolic process Effects 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 208000025061 parathyroid hyperplasia Diseases 0.000 claims description 2
- 230000002037 soft tissue calcification Effects 0.000 claims description 2
- 208000009852 uremia Diseases 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 description 10
- 125000002091 cationic group Chemical group 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161558389P | 2011-11-10 | 2011-11-10 | |
| US61/558,389 | 2011-11-10 | ||
| PCT/US2012/064717 WO2013071262A1 (en) | 2011-11-10 | 2012-11-12 | Calcimimetics and methods for their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017123032A Division JP2017160269A (ja) | 2011-11-10 | 2017-06-23 | カルシウム模倣薬およびその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015502346A JP2015502346A (ja) | 2015-01-22 |
| JP2015502346A5 true JP2015502346A5 (enExample) | 2016-01-07 |
| JP6204369B2 JP6204369B2 (ja) | 2017-09-27 |
Family
ID=47258113
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014541386A Active JP6204369B2 (ja) | 2011-11-10 | 2012-11-12 | カルシウム模倣薬およびその使用方法 |
| JP2017123032A Withdrawn JP2017160269A (ja) | 2011-11-10 | 2017-06-23 | カルシウム模倣薬およびその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017123032A Withdrawn JP2017160269A (ja) | 2011-11-10 | 2017-06-23 | カルシウム模倣薬およびその使用方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US20140315809A1 (enExample) |
| EP (1) | EP2776129B2 (enExample) |
| JP (2) | JP6204369B2 (enExample) |
| CN (2) | CN109985228A (enExample) |
| AU (1) | AU2012335009B2 (enExample) |
| CA (1) | CA2854911C (enExample) |
| HK (1) | HK1202086A1 (enExample) |
| MX (1) | MX355063B (enExample) |
| WO (1) | WO2013071262A1 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3404102T1 (sl) | 2004-04-21 | 2021-11-30 | Alexion Pharmaceuticals, Inc. | Konjugati za dodajanje kostem in njihova uporaba za ciljanje beljakovin na kosti |
| SMT201700014T1 (it) | 2009-07-29 | 2017-03-08 | Kai Pharmaceuticals Inc | Agenti terapeutici per la riduzione dei livelli dell'ormone paratiroideo |
| SI3013318T1 (sl) * | 2013-06-28 | 2017-11-30 | Amgen Inc. | Stabilna tekoča oblika amg 416 (velkalcetid) |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| TW201615222A (zh) * | 2014-10-24 | 2016-05-01 | 朗齊生物醫學股份有限公司 | 免疫疾病用藥臨床新應用 |
| RU2708068C2 (ru) | 2014-12-05 | 2019-12-04 | Алексион Фармасьютикалз, Инк. | Лечение судорог с использованием рекомбинантной щелочной фосфатазы |
| US9539264B2 (en) * | 2014-12-30 | 2017-01-10 | Wisconsin Alumni Research Foundation | Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics |
| JP6868561B2 (ja) * | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| MX2018002121A (es) | 2015-08-17 | 2018-06-18 | Alexion Pharma Inc | Elaboracion de fosfatasas alcalinas. |
| US11229686B2 (en) | 2015-09-28 | 2022-01-25 | Alexion Pharmaceuticals, Inc. | Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia |
| WO2017074466A1 (en) | 2015-10-30 | 2017-05-04 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| CN106928320B (zh) | 2015-12-31 | 2021-01-15 | 深圳翰宇药业股份有限公司 | 一种合成Etelcalcetide的方法 |
| EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN |
| WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| CN109152820A (zh) | 2016-04-01 | 2019-01-04 | 阿雷克森制药公司 | 用碱性磷酸酶治疗肌肉无力 |
| EP3464573A4 (en) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | EFFECTS OF METALS ON THE PRODUCTION OF ALKALINE PHOSPHATASES |
| US11116821B2 (en) | 2016-08-18 | 2021-09-14 | Alexion Pharmaceuticals, Inc. | Methods for treating tracheobronchomalacia |
| US11224637B2 (en) | 2017-03-31 | 2022-01-18 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (HPP) in adults and adolescents |
| WO2019190752A1 (en) | 2018-03-30 | 2019-10-03 | Alexion Pharmaceuticals, Inc. | Manufacturing of glycoproteins |
| EP3833377B1 (en) | 2018-08-10 | 2023-11-22 | Alexion Pharmaceuticals, Inc. | Bone healing at implants using alkaline phosphatase |
| EP3867650A1 (en) * | 2018-10-18 | 2021-08-25 | Fresenius Medical Care Holdings, Inc. | Techniques for modeling parathyroid gland functionality and calcimimetic drug activity |
| US12433938B2 (en) | 2019-12-09 | 2025-10-07 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| TW202122410A (zh) * | 2019-12-09 | 2021-06-16 | 大陸商北京拓界生物醫藥科技有限公司 | 鈣敏感受體激動劑化合物及其應用 |
| EP4212542A4 (en) * | 2020-09-10 | 2024-08-28 | Shaanxi Micot Technology Co., Ltd. | BISPECIFIC FUSION POLYPEPTIDE COMPOUND |
| US12083169B2 (en) | 2021-02-12 | 2024-09-10 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| CN117295510A (zh) * | 2021-06-08 | 2023-12-26 | 北京拓界生物医药科技有限公司 | 一种钙敏感受体激动剂的组合物及其应用 |
| CN117500820A (zh) * | 2021-06-08 | 2024-02-02 | 北京拓界生物医药科技有限公司 | 钙敏感受体激动剂化合物的盐酸盐及药物组合物和其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5602116A (en) | 1988-08-02 | 1997-02-11 | Bone Care International, Inc. | Method for treating and preventing secondary hyperparathyroidism |
| US5869473A (en) | 1988-08-02 | 1999-02-09 | Bone Care International, Inc. | Method for treating and preventing hyperparathyroidism |
| US5246925A (en) | 1989-03-09 | 1993-09-21 | Wisconsin Alumni Research Foundation | 19-nor-vitamin D compounds for use in treating hyperparathyroidism |
| CA1333616C (en) | 1989-03-09 | 1994-12-20 | Hector F. Deluca | 19-nor-vitamin d compounds |
| US5304121A (en) | 1990-12-28 | 1994-04-19 | Boston Scientific Corporation | Drug delivery system making use of a hydrogel polymer coating |
| US6031003A (en) | 1991-08-23 | 2000-02-29 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US6011068A (en) | 1991-08-23 | 2000-01-04 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| US5994341A (en) | 1993-07-19 | 1999-11-30 | Angiogenesis Technologies, Inc. | Anti-angiogenic Compositions and methods for the treatment of arthritis |
| US6099562A (en) | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
| AU3819497A (en) * | 1996-07-31 | 1998-02-20 | General Hospital Corporation, The | Novel parathyroid hormone-related peptide analogs |
| US6051567A (en) | 1999-08-02 | 2000-04-18 | Abbott Laboratories | Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol |
| US6274169B1 (en) | 1999-08-02 | 2001-08-14 | Abbott Laboratories | Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol |
| EP1301479A2 (en) | 2000-07-18 | 2003-04-16 | Bone Care International, Inc. | STABILIZED 1$g(a)-HYDROXY VITAMIN D |
| WO2003013543A1 (en) * | 2001-08-08 | 2003-02-20 | Genomed, Llc | Treatment or prevention of acute renal failure |
| US20060276534A1 (en) * | 2005-03-17 | 2006-12-07 | Amgen Inc. | Methods of decreasing calcification |
| WO2008067199A2 (en) | 2006-11-16 | 2008-06-05 | Kai Pharmaceuticals, Inc. | Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders |
| US20080261926A1 (en) * | 2007-04-02 | 2008-10-23 | Liu Julie F | Pharmaceutical Calcimimetics |
| SMT201700014T1 (it) * | 2009-07-29 | 2017-03-08 | Kai Pharmaceuticals Inc | Agenti terapeutici per la riduzione dei livelli dell'ormone paratiroideo |
| GB0913525D0 (en) * | 2009-08-03 | 2009-09-16 | Ineos Healthcare Ltd | Method |
-
2012
- 2012-11-12 AU AU2012335009A patent/AU2012335009B2/en active Active
- 2012-11-12 CA CA2854911A patent/CA2854911C/en active Active
- 2012-11-12 CN CN201910103503.4A patent/CN109985228A/zh active Pending
- 2012-11-12 EP EP12791926.4A patent/EP2776129B2/en active Active
- 2012-11-12 WO PCT/US2012/064717 patent/WO2013071262A1/en not_active Ceased
- 2012-11-12 MX MX2014005662A patent/MX355063B/es active IP Right Grant
- 2012-11-12 JP JP2014541386A patent/JP6204369B2/ja active Active
- 2012-11-12 CN CN201280066707.1A patent/CN104168955A/zh active Pending
- 2012-11-12 US US14/357,702 patent/US20140315809A1/en not_active Abandoned
- 2012-11-12 HK HK15102648.5A patent/HK1202086A1/xx unknown
-
2016
- 2016-03-01 US US15/057,742 patent/US20160175383A1/en not_active Abandoned
-
2017
- 2017-05-23 US US15/603,279 patent/US20170252397A1/en not_active Abandoned
- 2017-06-23 JP JP2017123032A patent/JP2017160269A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015502346A5 (enExample) | ||
| JP2015522576A5 (enExample) | ||
| JP2010166916A5 (enExample) | ||
| MX2011012131A (es) | Perhexilina para usarla en el tratamiento de miocardiopatía hipertrófica (hcm). | |
| CY1120049T1 (el) | (2s)-ν-[(1s)-1-κυανο-2-φαινυλαιθυλ]-1,4-οξαζεπαν-2-καρβοξαμιδια ως αναστολεις της διπεπτιδυλικης πεπτιδασης i | |
| JP2013518815A5 (enExample) | ||
| JP2010202664A5 (enExample) | ||
| NO20101036L (no) | Behandle og profylakse av amyloidose | |
| JP2012529293A5 (enExample) | ||
| JP2012115277A5 (enExample) | ||
| JP2013539454A5 (enExample) | ||
| JP2013520405A5 (enExample) | ||
| RU2015120804A (ru) | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений | |
| JP2011105739A5 (enExample) | ||
| JP2014051497A5 (enExample) | ||
| EA201391581A1 (ru) | Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств | |
| JP2012136541A5 (enExample) | ||
| EA201691759A1 (ru) | Композиции и способы лечения легочной гипертензии | |
| JP2013503110A5 (enExample) | ||
| WO2012159052A3 (en) | Targeted delivery of proteins across the blood brain barrier | |
| JP2017511377A5 (enExample) | ||
| JP2012513193A5 (enExample) | ||
| MX354535B (es) | TRATAMIENTO DE INFARTO DE MIOCARDIO USANDO ANTAGONISTAS DE TGF-ß. | |
| JP2018516944A5 (enExample) | ||
| MX2015006720A (es) | D-metadona para el tratamiento de sintomas psiquiatricos. |